Literature DB >> 8485123

Identification of multiple dense LDL subfractions with enhanced susceptibility to in vitro oxidation among hypertriglyceridemic subjects. Normalization after clofibrate treatment.

J de Graaf1, J C Hendriks, P N Demacker, A F Stalenhoef.   

Abstract

The influence of different plasma triglyceride concentrations on the heterogeneity of low density lipoprotein (LDL) and on the susceptibility of LDL to copper oxidation was investigated. By density gradient ultracentrifugation, LDL subfractions were isolated from the plasma of 10 normolipidemic control subjects and 12 hypertriglyceridemic patients both before and after clofibrate treatment. In the plasma of control subjects three LDL subfractions were present: LDL1 (d = 1.030-1.033 g/mL), LDL2 (d = 1.033-1.040 g/mL), and LDL3 (d = 1.040-1.045 g/mL). In the plasma of nine moderately hypertriglyceridemic subjects up to five LDL subfractions could be detected: LDL1-LDL3, LDL4 (d = 1.045-1.049 g/mL), and LDL5 (d = 1.049-1.054 g/mL). This polydispersity of LDL was replaced by monodispersity with increasing plasma triglyceride concentrations in three subjects with chylomicronemia, in whom LDL was concentrated in the narrow LDL5 density range. Clofibrate treatment resulted in a lighter LDL subfraction pattern (LDL1-LDL4). In both the control and the moderately hypertriglyceridemic subjects, the small dense LDL subfractions appeared more prone to oxidative modification in vitro than the light LDL subfractions, as measured by the decreased lag time preceding the onset of lipid peroxidation. Furthermore, the dense LDL subfractions were more extensively modified over time, as shown by an increased oxidation rate and a greater number of dienes formed after 6 hours of oxidation. These results suggest an enhanced atherogenic potential of the small, dense LDL subfractions within each LDL subfraction profile. The hypertriglyceridemic LDL subfractions before therapy (LDL3-LDL5) were less resistant to in vitro oxidation than the light, control LDL subfractions (LDL1-LDL3).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8485123     DOI: 10.1161/01.atv.13.5.712

Source DB:  PubMed          Journal:  Arterioscler Thromb        ISSN: 1049-8834


  11 in total

Review 1.  Postprandial lipemia and coronary risk.

Authors:  W Patsch; H Esterbauer; B Föger; J R Patsch
Journal:  Curr Atheroscler Rep       Date:  2000-05       Impact factor: 5.113

Review 2.  The role of fibric acid derivatives in the secondary prevention of coronary heart disease.

Authors:  J Krakoff; B S Vela; E A Brinton
Journal:  Curr Cardiol Rep       Date:  2000-09       Impact factor: 2.931

3.  Lipoprotein composition and oxidative modification during therapy with gemfibrozil and lovastatin in patients with combined hyperlipidaemia.

Authors:  M Vázquez; D Zambón; Y Hernández; T Adzet; M Merlos; E Ros; J C Laguna
Journal:  Br J Clin Pharmacol       Date:  1998-03       Impact factor: 4.335

Review 4.  Fibrates for secondary prevention of cardiovascular disease and stroke.

Authors:  Deren Wang; Bian Liu; Wendan Tao; Zilong Hao; Ming Liu
Journal:  Cochrane Database Syst Rev       Date:  2015-10-25

5.  A common genetic mechanism determines plasma apolipoprotein B levels and dense LDL subfraction distribution in familial combined hyperlipidemia.

Authors:  S H Juo; S J Bredie; L A Kiemeney; P N Demacker; A F Stalenhoef
Journal:  Am J Hum Genet       Date:  1998-08       Impact factor: 11.025

Review 6.  Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM).

Authors:  B H Wolffenbuttel; T W van Haeften
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

7.  Oxidation of low-density lipoprotein in NIDDM: its relationship to fatty acid composition.

Authors:  E Dimitriadis; M Griffin; D Owens; A Johnson; P Collins; G H Tomkin
Journal:  Diabetologia       Date:  1995-11       Impact factor: 10.122

Review 8.  The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy.

Authors:  Sergio Fazio; MacRae F Linton
Journal:  Curr Atheroscler Rep       Date:  2004-03       Impact factor: 5.113

9.  Ezetimibe's effect on platelet aggregation and LDL tendency to peroxidation in hypercholesterolaemia as monotherapy or in addition to simvastatin.

Authors:  Osamah Hussein; Lilia Minasian; Yaroslav Itzkovich; Karina Shestatski; Lizora Solomon; Jamal Zidan
Journal:  Br J Clin Pharmacol       Date:  2008-01-30       Impact factor: 4.335

Review 10.  Re-emergence of fibrates in the management of dyslipidemia and cardiovascular risk.

Authors:  M F Linton; S Fazio
Journal:  Curr Atheroscler Rep       Date:  2000-01       Impact factor: 5.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.